Bellicum Pharmaceuticals nabs $55 mln Series C
Bellicum Pharmaceuticals has closed $55 million in Series C funding. The investors included funds managed by RA Capital Management, Perceptive Advisors, Jennison Associates (on behalf of certain clients), Sabby Capital and Ridgeback Capital Management. Jefferies was the placement agent. Based in Houston, Bellicum Pharmaceuticals is a biotech firm focused on developing cellular immunotherapies.
27 August 2014•2 mins read
